CVE-2023-20052

Description

On Feb 15, 2023, the following vulnerability in the ClamAV scanning library was disclosed: A vulnerability in the DMG file parser of ClamAV versions 1.0.0 and earlier, 0.105.1 and earlier, and 0.103.7 and earlier could allow an unauthenticated, remote attacker to access sensitive information on an affected device. This vulnerability is due to enabling XML entity substitution that may result in XML external entity injection. An attacker could exploit this vulnerability by submitting a crafted DMG file to be scanned by ClamAV on an affected device. A successful exploit could allow the attacker to leak bytes from any file that may be read by the ClamAV scanning process.

Categories

5.3
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 7.18% Top 10%
Vendor Advisory cisco.com
Affected: Cisco Cisco Secure Endpoint
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2023-20052?
CVE-2023-20052 has been scored as a medium severity vulnerability.
How to fix CVE-2023-20052?
To fix CVE-2023-20052, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2023-20052 being actively exploited in the wild?
It is possible that CVE-2023-20052 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~7% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2023-20052?
CVE-2023-20052 affects Cisco Cisco Secure Endpoint.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.